Beneficial Ownership Report · SCHEDULE 13G
Yarrow Bioscience, Inc.
YARWNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G
primary_doc.xml
Subject company
- Company
- Yarrow Bioscience, Inc.
- Company CIK
- 0001566044
- Street
- 470 James Street
- Street (continued)
- Suite 007
- City
- New Haven
- State / country code
- CT
- Postal code
- 06513
Statement details
- Security class
- Common Stock
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(b)
Reporting person 1
- Name
- Ameriprise Financial, Inc.
- Citizenship / organization
- DE
- Reporting person type
- HC
- Group designation
- b
- Aggregate amount owned
- 739,538
- Percent of class
- 8.6
- Sole voting power
- 0
- Shared voting power
- 724,391
- Sole dispositive power
- 0
- Shared dispositive power
- 739,538
- Aggregate excludes certain shares
- N
Reporting person 2
- Name
- Columbia Management Investment Advisers, LLC
- Citizenship / organization
- MN
- Reporting person type
- IA
- Group designation
- b
- Aggregate amount owned
- 739,538
- Percent of class
- 8.6
- Sole voting power
- 0
- Shared voting power
- 724,391
- Sole dispositive power
- 0
- Shared dispositive power
- 739,538
- Aggregate excludes certain shares
- N
Reporting person 3
- Name
- Columbia Small Cap Growth Fund
- Citizenship / organization
- MA
- Reporting person type
- IV
- Group designation
- b
- Aggregate amount owned
- 539,115
- Percent of class
- 6.3
- Sole voting power
- 539,115
- Shared voting power
- 0
- Sole dispositive power
- 0
- Shared dispositive power
- 539,115
- Aggregate excludes certain shares
- N
Item 1
Issuer
Yarrow Bioscience, Inc.
Principal executive office address
470 James Street, Suite 007, New Haven, CT 06513
Item 2
Citizenship
(a) Delaware (b) Minnesota (c) Massachusetts
Filing person
(a) Ameriprise Financial, Inc. ("AFI") (b) Columbia Management Investment Advisers, LLC ("CMIA") (c) Columbia Small Cap Growth Fund ("FUND")
Principal business or residence address
(a) 145 Ameriprise Financial Center, Minneapolis, MN 55474 (b) 290 Congress Street, Boston, MA 02210 (c) 290 Congress Street, Boston, MA 02210
Item 3
Not applicable indication
N
Type of filing person
HC
Item 4
Percent of class
The information required by Item 4(b) is set forth in Rows (5)-(9) and (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.
Amount beneficially owned
Incorporated by reference to Items (5)-(9) and (11) of the cover page pertaining to each reporting person. CMIA and AFI do not directly own any shares of Common Stock of the issuer. As the investment adviser to the Fund and various other unregistered and registered investment companies and other managed accounts, CMIA may be deemed to beneficially own the shares reported herein by the Fund. Accordingly, the shares reported herein by CMIA include those shares separately reported herein by the Fund. As the parent holding company of CMIA, AFI may be deemed to beneficially own the shares reported herein by CMIA. Accordingly, the shares reported herein by AFI include those shares separately reported herein by CMIA. Each of AFI and CMIA, and the subsidiaries identified on the attached Exhibit I, disclaims beneficial ownership of any shares reported on this Schedule.
Sole voting power
The information required by Item 4(c) is set forth in Rows (5)-(9) and (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.
Shared voting power
The information required by Item 4(c) is set forth in Rows (5)-(9) and (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.
Sole dispositive power
The information required by Item 4(c) is set forth in Rows (5)-(9) and (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.
Shared dispositive power
The information required by Item 4(c) is set forth in Rows (5)-(9) and (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.
Item 5
Not applicable indication
Y
Item 6
Not applicable indication
N
Ownership on behalf of another person
To the knowledge of AFI, CMIA and the Fund, no other persons besides AFI, CMIA and the Fund and those persons for whose shares of common stock CMIA and AFI report beneficial ownership have the right to receive or the power to direct the receipt of dividends from or the proceeds from the sale of the securities of the issuer reported herein. As of September 30, 2026, only the Fund owned more than 5% of the class of securities reported herein. Any remaining shares reported herein by CMIA are held by various other funds or accounts managed by CMIA which each have the right to receive any dividends paid by the issuer and could terminate their respective investment advisory relationship with CMIA and then subsequently direct the use of proceeds from the sale of the common stock owned by such fund or account. To CMIA's knowledge, none of these other funds or accounts own more than 5% of the outstanding shares of the issuer as of September 30, 2026.
Item 7
Not applicable indication
N
Subsidiaries
AFI: See Exhibit I
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Exhibits
Exhibit Index Exhibit I Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company. Exhibit II Joint Filing Agreement
Signature comments
Contact Information Charles Chiesa VP Fund Treasurer Global Operations and Investor Services Telephone: 617-385-9593
Signature 1
- Reporting person
- Ameriprise Financial, Inc.
- Signed
- /s/ Michael G. Clarke
- Title
- Michael G. Clarke, Senior Vice President, North America Head of Operations & Investor Services
- Date
- 11/16/2026
Signature 2
- Reporting person
- Columbia Management Investment Advisers, LLC
- Signed
- /s/ Michael G. Clarke
- Title
- Michael G. Clarke, Senior Vice President, North America Head of Operations & Investor Services
- Date
- 11/16/2026
Signature 3
- Reporting person
- Columbia Small Cap Growth Fund
- Signed
- /s/ Michael G. Clarke
- Title
- Michael G. Clarke, Senior Vice President & Chief Financial Officer
- Date
- 11/16/2026
Filed exhibits
- EX-99.I ↗ck0000000000-ex99_i.pdf
- EX-99.II ↗ck0000000000-ex99_ii.pdf
Company context
Yarrow Bioscience, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company is developing YB-101, a potentially first-in-class anti-thyroid stimulating hormone receptor (“TSHR”) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both GD and TED. For more information, visit www.yarrowbioscience.com.
Current securities
Historical securities (1)
Recent company filings
- SCHEDULE 13G/A - filed by PERCEPTIVE ADVISORS LLC regarding Yarrow Bioscience, Inc.Nov 16, 2026
- SCHEDULE 13G/A - filed by Janus Henderson Group Ltd. regarding Yarrow Bioscience, Inc.Nov 16, 2026
- S-8 filingNov 13, 2026
- SCHEDULE 13G/A - filed by Nantahala Capital Management, LLC regarding Yarrow Bioscience, Inc.Nov 13, 2026
- 10-Q filingNov 13, 2026